A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis
Simon R. Best(Johns Hopkins University), Karen B. Zur(Children's Hospital of Philadelphia), Nicole Fowler(Royal Cornwall Hospital Trust), Jonathan M. Bock(Medical College of Wisconsin), Douglas R. Sidell(Lucile Packard Children's Hospital), Nabil F. Saba(Emory University), Rico N. P. M. Rinkel(Amsterdam University Medical Centers), Eric H. Raabe(Johns Hopkins University), James B. Tansey(Lawrence Foundation), Kim McClellan(Lawrence Foundation), Theodore W. Laetsch(Children's Hospital of Philadelphia), David E. Tunkel(Johns Hopkins University), Geoffrey D. Young(Nationwide Children's Hospital), Adam M. Klein(Emory University)
Cited by 14
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck cancer
|The Lancet|2021|829
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711